Tuesday, January 06, 2015 1:58:49 PM
Depression, as many of us know, is more than just a sad or melancholy mood. It’s more than just having “the blues.” Sometimes it can be a very debilitating condition that can prevent people from having productive lives – and in some cases can be a root cause of suicide and/or fatal drug overdoses.
Depression is often considered an imbalance of certain chemicals in the brain, and is treated through various therapies and anti-depressant drugs. However, the very serious level of depression – the living-in-an-abyss type of depression that was behind the recent death of actor and comedian Robin Williams (also known as Major Depressive Disorder, or MDD) – has been very difficult to treat effectively. There has been a trade-off with some therapies – there are some strong anti-depressants in the market, but most have side effects that can be dangerous in their own right – perhaps more so than the depression itself. VistaGen Therapeutics, Inc. (OTCQB: VSTA) is looking to fill this very important mental-health gap with its own potential new antidepressant therapy known as AV-101.
VistaGen’s AV-101 has gone through the initial Phase 1 clinical development focused on human safety and the company is now working toward a significant Phase 2 clinical trial of AV-101 in collaboration with the U.S. National Institutes of Health (NIH). The NIH previously awarded the company nearly $9 million for its preclinical and Phase 1 development programs, and the company expects the NIH to sponsor and conduct the impending Phase 2 efficacy study. VistaGen believes AV-101 is a potential new generation antidepressant with a novel mechanism of action to address MDD more rapidly and with fewer and less-severe side effects than other depression therapies currently being used.
With a successful Phase 2 trial which is expected to be completed by the end of 2015, there could be some significant momentum for VistaGen Therapeutics in the mental-health sector, with AV-101 as a novel potential therapy for MDD and other similar mood disorders that affect millions of Americans. Robin Williams’ sad and tragic death has brought MDD more prominently into the forefront, and it will be therapies like AV-101 that will be watched more readily as mental-health professionals look to encourage more diagnoses of depression and other mood disorders so they can be treated early and aggressively. This is an environment for VistaGen Therapeutics to be in the spotlight.
For more information, visit www.vistagen.com
Recent VTGN News
- Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue • Business Wire • 04/25/2024 12:30:00 PM
- Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference • Business Wire • 04/09/2024 12:30:00 PM
- Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 • Business Wire • 04/01/2024 12:30:00 PM
- Vistagen to Present at Stifel 2024 Virtual CNS Days • Business Wire • 03/11/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 11:00:10 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/01/2024 05:15:07 AM
- Vistagen to Present at TD Cowen 44th Annual Health Care Conference • Business Wire • 02/28/2024 01:30:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:18:34 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:51:40 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:56:03 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 02/13/2024 09:52:47 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:33:59 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/13/2024 09:25:18 PM
- Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update • Business Wire • 02/13/2024 09:20:00 PM
- Vistagen to Report Fiscal Year 2024 Third Quarter Financial Results and Host Corporate Update Conference Call on February 13, 2024 • Business Wire • 02/06/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:19:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2024 10:17:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:09:52 PM
- Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain • Business Wire • 12/27/2023 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:44:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:42:34 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM